Table 4.
Vaccination related immune response to p53 peptide 1–6 as evaluated by Elispot
| Patient number | p53 peptide specific T cell reactivity (peptide number according to Table 1) | |||
|---|---|---|---|---|
| Pre-existing | Induced | Increased | Reduced | |
| Response at one evaluation | ||||
| 14 | 1,2,3,4 | 5,6 | 2,4 | |
| 15 | 4,5,6 | |||
| 29 | 1,2,3,4,5,6 | |||
| 35 | 1,2,4 | |||
| PD at 1.evaluation | ||||
| 13 | 1 | |||
| 27 | 3,4 | 3,4 | ||
| 36 | 1,2,3,4,6 | 1,2,3,4,6 | ||
| 38 | 1 | |||
| Early termination | ||||
| 12 | 3,4,6 | 1,5 | 6 | |
| 18 | 2,3,4,5,6 | 1 | 2,5,6 | |
Elispot responses were defined as positive when the number of spots was >20 and more than 2 background (vehicle). Induced or increased responses was defined as responses >2 pre-vaccine levels, and reduced responses was defined as responses 2< prevaccine levels at a given time point. Data represents means of triplicates with background subtracted